MSD's Tulisokibart: Best-in-Class UC Signal Tempered by Indication Failure and Peer Safety Flags

MSD's Tulisokibart Shows Phase II Success in Hidradenitis Suppurativa

MSD announced mixed Phase II results for its anti-TL1A therapy, tulisokibart, during its Q2 earnings call. The drug achieved both primary and secondary endpoints in a trial for hidradenitis suppurativa (HS), demonstrating significant abscess and nodule clearance and improved quality of life. However, tulisokibart failed to show a significant impact in the ATHENA-SSc-ILD trial for systemic sclerosis-associated interstitial lung disease (SSc-ILD), leading MSD to discontinue its development for this rare lung condition. This drug was acquired through MSD's $10.8 billion acquisition of Prometheus Biosciences in 2023. Despite the SSc-ILD setback, tulisokibart continues to be evaluated across multiple indications, including positive Phase III data in ulcerative colitis, as MSD seeks to bolster its pipeline ahead of Keytruda's patent expiry in 2028.

• Positive Phase II Results in Hidradenitis Suppurativa: Tulisokibart successfully met both its primary and secondary endpoints in a Phase II trial (NCT06956235) for hidradenitis suppurativa (HS). The trial demonstrated over 50% clearance of abscesses and nodules, alongside improvements in quality of life and a favorable adverse event profile. MSD plans to present further detailed results from this successful trial at an upcoming medical conference.
• Discontinuation in Systemic Sclerosis-Associated Interstitial Lung Disease: In contrast, tulisokibart failed to achieve a significant impact in the Phase II ATHENA-SSc-ILD trial (NCT05270668) for systemic sclerosis-associated interstitial lung disease (SSc-ILD). Consequently, MSD has decided to discontinue the drug's development for this rare lung disease, a program inherited from its 2023 acquisition of Prometheus Biosciences for $10.8 billion.
• Broad Anti-TL1A Pipeline and Strategic Importance: The anti-TL1A drug class, including tulisokibart, is a focus for major pharmaceutical companies due to its 'pipeline-in-a-product' potential across various inflammatory and rheumatological conditions. Tulisokibart currently boasts the broadest development program among anti-TL1As, with ongoing trials in ulcerative colitis (where it showed positive Phase III data in June 2026), Crohn’s disease, rheumatoid arthritis, radiographic axial spondyloarthritis, and psoriatic arthritis, crucial for MSD's post-Keytruda strategy.

Tulisokibart's Broad Pipeline Beyond Hidradenitis Suppurativa

Tulisokibart, a monoclonal antibody targeting tumor necrosis factor-like cytokine 1A (TL1A), is being explored for indications beyond hidradenitis suppurativa. Clinical development is focused on inflammatory bowel diseases, with trials investigating its efficacy and safety in patients with moderately to severely active ulcerative colitis and Crohn's disease.

The Unmet Needs in Hidradenitis Suppurativa Treatment

Current therapeutic approaches for Hidradenitis Suppurativa (HS) are characterized by significant limitations, often failing to provide durable remission for this chronic inflammatory disease. Many patients cycle through available treatments with variable success, highlighting a substantial unmet need for more effective and sustainable management strategies that can address both the cutaneous and systemic aspects of the disease.

• High Rates of Treatment Failure and Inadequate Response: A primary challenge is the high frequency of treatment failure across modalities. Many patients with moderate-to-severe HS exhibit inadequate or unsustained responses to approved biologic agents targeting TNF-α and IL-17A, and secondary failure can occur even after years of effective therapy.

• Variable Efficacy of Traditional Therapies: Traditional management with systemic retinoids, antibiotics, and surgical interventions yields highly variable therapeutic responses. Achieving long-term remission with these approaches remains difficult, and they are often insufficient for managing severe, refractory disease.

• Limitations of Non-Biologic Options: While antibiotics are a mainstay for mild-to-moderate HS, their use contributes to antibiotic pressure and the development of microbial resistance. Furthermore, evidence regarding the efficacy and safety of alternative treatments, such as topical 15% resorcinol, is limited.

• Significant Patient Treatment Burden: The burden of therapy itself considerably reduces health-related quality of life for patients. Over half of individuals with HS (54.3%) report issues with their treatment, which can significantly impact their daily lives and overall well-being.

Tulisokibart's Mixed Fortunes: A Strategic Pivot for MSD's Pipeline

The recent announcement regarding tulisokibart, MSD's anti-TL1A therapy acquired through the Prometheus Biosciences deal, presents a nuanced picture for the company's immunology pipeline. While the drug delivered compelling Phase II results in hidradenitis suppurativa (HS), demonstrating significant clinical improvements, it simultaneously failed to meet endpoints in systemic sclerosis-associated interstitial lung disease (SSc-ILD). This mixed outcome is a critical juncture for MSD, particularly as it seeks to fortify its portfolio ahead of Keytruda's patent expiration.

The success in HS is a significant win. Research indicates that TL1A plays a pivotal role in immune pathways driving inflammation and fibrosis, and its inhibition has shown promise in various immune-mediated diseases. The positive HS data validates this mechanism in a chronic, debilitating skin condition where current treatments often fall short, opening a new and important therapeutic avenue for tulisokibart. This expands the drug's potential beyond its well-documented efficacy in inflammatory bowel disease (IBD), where studies have shown anti-TL1A antibodies to be effective in inducing clinical remission in ulcerative colitis (UC) and Crohn's disease (CD).

However, the SSc-ILD setback cannot be overlooked. While TL1A is implicated in fibrosis, this failure suggests that the specific fibrotic pathways or disease heterogeneity in SSc-ILD may not be amenable to TL1A inhibition, or that patient selection requires further refinement. This outcome will likely prompt a more focused development strategy, prioritizing indications where the mechanism has shown clear benefit.

For MSD, the strategic implications are clear:

• Reinforced IBD Focus: The strong Phase III data in UC, coupled with the precision medicine approach utilizing a genetic diagnostic test, positions tulisokibart as a potentially differentiated therapy in a competitive IBD market.

• Expanded Immunology Footprint: The HS success provides a valuable new indication, diversifying MSD's immunology offerings and leveraging the TL1A platform's broader potential.

• Pipeline Prioritization: The SSc-ILD failure will necessitate a critical review of other potential fibrotic indications, ensuring resources are allocated to the most promising opportunities.

The path forward for tulisokibart will involve navigating a complex competitive landscape, particularly in IBD where numerous novel agents are emerging. The successful integration of the genetic diagnostic test will be crucial for optimizing patient outcomes and market access. Ultimately, these mixed results underscore the importance of targeted development and patient stratification in realizing the full potential of novel therapeutic mechanisms like TL1A inhibition.